Last $3.25 USD
Change Today 0.00 / 0.00%
Volume 0.0
RESX On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 12/16/14 All times are local (Market data is delayed by at least 15 minutes).

restorgenex corp (RESX) Snapshot

Open
$3.35
Previous Close
$3.25
Day High
$3.35
Day Low
$3.25
52 Week High
03/27/14 - $10.20
52 Week Low
03/5/14 - $2.37
Market Cap
60.5M
Average Volume 10 Days
251.6
EPS TTM
$-1.04
Shares Outstanding
18.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RESTORGENEX CORP (RESX)

Related News

No related news articles were found.

restorgenex corp (RESX) Related Businessweek News

No Related Businessweek News Found

restorgenex corp (RESX) Details

RestorGenex Corporation operates as a specialty biopharmaceutical company that focuses on developing products for dermatology, ophthalmology, and women’s health. Its product under development includes HYG-102, a soft estrogen for the treatment of aging skin fragility/thinning; HYG-440, a soft anti-androgen for the treatment of androgen excess, e.g. acne, male-pattern baldness, and hirsutism; and P529, a prescription dermatology compound used for the treatment of keloid scarring, psoriasis, atopic dermatitis, rosacea, actinic keratosis, Dupuytren’s disease, and the bullous blistering diseases. RestorGenex Corporation has Collaboration Agreement with Ferndale Pharma Group, Inc. for developing aging skin product. The company was formerly known as Stratus Media Group, Inc. and changed its name to RestorGenex Corporation in March 2014. RestorGenex Corporation is based in Los Angeles, California.

restorgenex corp (RESX) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

restorgenex corp (RESX) Key Developments

Restorgenex Corporation Announces Auditor Changes

On November 20, 2014, RestorGenex Corporation engaged Deloitte & Touche LLP (D&T) as the company’s new independent registered public accounting firm after dismissing Goldman Kurland and Mohidin LLP (GKM). On November 20, 2014, the company dismissed GKM, as the company’s independent registered public accounting firm. The Audit Committee of the Board of Directors of the company approved GKM’s dismissal on November 20, 2014.

Restorgenex Corporation Reports Earnings Results for the Third Quarter Ended September 30, 2014

Restorgenex Corporation reported earnings results for the third quarter ended September 30, 2014. For the quarter, the company reported net loss of approximately $3.5 million or $0.18 loss per share compared to a net loss of $1.5 million or $0.37 loss per share for the same period in 2013. The increase in the net loss was due primarily to higher expenses in 2014 associated with the company's research and development efforts to advance its technologies and products.

RestorGenex Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2014

RestorGenex Corporation reported earnings results for the second quarter ended June 30, 2014. The company incurred a net loss of approximately $4.5 million or $0.35 per share for the quarter ended June 30, 2014, compared to net income of $2.3 million or $0.82 per share for the same period in 2013. The increase in the net loss was due primarily to $10.6 million in other income recognized in 2013 for non-cash gains on adjustments to the fair value of the company's previously owned derivative liability and extinguishment of that derivative liability combined with higher expenses in 2014 associated with the Company's research and development efforts to advance its technologies and products.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RESX:US $3.25 USD 0.00

RESX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RESX.
View Industry Companies
 

Industry Analysis

RESX

Industry Average

Valuation RESX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 846.7x
Price/Book 1.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 508.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RESTORGENEX CORP, please visit www.stratusmediagroup.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.